<?xml version='1.0' encoding='utf-8'?>
<document id="25636696"><sentence text="Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study."><entity charOffset="51-65" id="DDI-PubMed.25636696.s1.e0" text="sodium glucose" /><entity charOffset="92-105" id="DDI-PubMed.25636696.s1.e1" text="empagliflozin" /><entity charOffset="110-129" id="DDI-PubMed.25636696.s1.e2" text="hydrochlorothiazide" /><entity charOffset="133-143" id="DDI-PubMed.25636696.s1.e3" text="torasemide" /><pair ddi="false" e1="DDI-PubMed.25636696.s1.e0" e2="DDI-PubMed.25636696.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25636696.s1.e0" e2="DDI-PubMed.25636696.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s1.e0" e2="DDI-PubMed.25636696.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s1.e0" e2="DDI-PubMed.25636696.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s1.e1" e2="DDI-PubMed.25636696.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s1.e1" e2="DDI-PubMed.25636696.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s1.e1" e2="DDI-PubMed.25636696.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s1.e2" e2="DDI-PubMed.25636696.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s1.e2" e2="DDI-PubMed.25636696.s1.e3" /></sentence><sentence text="Empagliflozin is a potent, selective sodium glucose cotransporter 2 inhibitor approved for the treatment of type 2 diabetes mellitus"><entity charOffset="0-13" id="DDI-PubMed.25636696.s2.e0" text="Empagliflozin" /><entity charOffset="37-51" id="DDI-PubMed.25636696.s2.e1" text="sodium glucose" /><pair ddi="false" e1="DDI-PubMed.25636696.s2.e0" e2="DDI-PubMed.25636696.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25636696.s2.e0" e2="DDI-PubMed.25636696.s2.e1" /></sentence><sentence text=" Thiazide or loop diuretics are commonly prescribed in patients with type 2 diabetes mellitus"><entity charOffset="1-9" id="DDI-PubMed.25636696.s3.e0" text="Thiazide" /></sentence><sentence text=" This study investigated potential pharmacokinetic drug-drug interactions between empagliflozin and hydrochlorothiazide (HCTZ) or torasemide (TOR)"><entity charOffset="82-95" id="DDI-PubMed.25636696.s4.e0" text="empagliflozin" /><entity charOffset="100-119" id="DDI-PubMed.25636696.s4.e1" text="hydrochlorothiazide" /><entity charOffset="121-125" id="DDI-PubMed.25636696.s4.e2" text="HCTZ" /><entity charOffset="130-140" id="DDI-PubMed.25636696.s4.e3" text="torasemide" /><entity charOffset="142-145" id="DDI-PubMed.25636696.s4.e4" text="TOR" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e0" e2="DDI-PubMed.25636696.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e0" e2="DDI-PubMed.25636696.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e0" e2="DDI-PubMed.25636696.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e0" e2="DDI-PubMed.25636696.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e0" e2="DDI-PubMed.25636696.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e1" e2="DDI-PubMed.25636696.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e1" e2="DDI-PubMed.25636696.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e1" e2="DDI-PubMed.25636696.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e1" e2="DDI-PubMed.25636696.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e2" e2="DDI-PubMed.25636696.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e2" e2="DDI-PubMed.25636696.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e2" e2="DDI-PubMed.25636696.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e3" e2="DDI-PubMed.25636696.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s4.e3" e2="DDI-PubMed.25636696.s4.e4" /></sentence><sentence text="" /><sentence text="This was an open-label, crossover study" /><sentence text=" Patients with type 2 diabetes mellitus were randomized to receive empagliflozin 25 mg once daily for 5 days and either HCTZ 25 mg once daily for 4 days followed by HCTZ 25 mg once daily plus empagliflozin 25 mg once daily for 5 days or TOR 5 mg once daily for 4 days followed by TOR 5 mg once daily plus empagliflozin once daily for 5 days in 1 of 4 sequences, with at least a 7-day washout period between treatments"><entity charOffset="67-80" id="DDI-PubMed.25636696.s7.e0" text="empagliflozin" /><entity charOffset="192-205" id="DDI-PubMed.25636696.s7.e1" text="empagliflozin" /><entity charOffset="305-318" id="DDI-PubMed.25636696.s7.e2" text="empagliflozin" /><entity charOffset="120-132" id="DDI-PubMed.25636696.s7.e3" text="HCTZ" /><entity charOffset="165-177" id="DDI-PubMed.25636696.s7.e4" text="HCTZ" /><entity charOffset="237-249" id="DDI-PubMed.25636696.s7.e5" text="TOR" /><entity charOffset="280-292" id="DDI-PubMed.25636696.s7.e6" text="TOR" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e0" e2="DDI-PubMed.25636696.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e0" e2="DDI-PubMed.25636696.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e0" e2="DDI-PubMed.25636696.s7.e4" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e0" e2="DDI-PubMed.25636696.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e0" e2="DDI-PubMed.25636696.s7.e5" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e0" e2="DDI-PubMed.25636696.s7.e6" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e0" e2="DDI-PubMed.25636696.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e3" e2="DDI-PubMed.25636696.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e3" e2="DDI-PubMed.25636696.s7.e4" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e3" e2="DDI-PubMed.25636696.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e3" e2="DDI-PubMed.25636696.s7.e5" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e3" e2="DDI-PubMed.25636696.s7.e6" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e3" e2="DDI-PubMed.25636696.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e4" e2="DDI-PubMed.25636696.s7.e4" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e4" e2="DDI-PubMed.25636696.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e4" e2="DDI-PubMed.25636696.s7.e5" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e4" e2="DDI-PubMed.25636696.s7.e6" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e4" e2="DDI-PubMed.25636696.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e1" e2="DDI-PubMed.25636696.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e1" e2="DDI-PubMed.25636696.s7.e5" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e1" e2="DDI-PubMed.25636696.s7.e6" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e1" e2="DDI-PubMed.25636696.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e5" e2="DDI-PubMed.25636696.s7.e5" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e5" e2="DDI-PubMed.25636696.s7.e6" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e5" e2="DDI-PubMed.25636696.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e6" e2="DDI-PubMed.25636696.s7.e6" /><pair ddi="false" e1="DDI-PubMed.25636696.s7.e6" e2="DDI-PubMed.25636696.s7.e2" /></sentence><sentence text=" Pharmacokinetic parameters of empagliflozin, HCTZ, and TOR were assessed and standard bioequivalence criteria (80%-125%) were applied"><entity charOffset="31-44" id="DDI-PubMed.25636696.s8.e0" text="empagliflozin" /><entity charOffset="46-50" id="DDI-PubMed.25636696.s8.e1" text="HCTZ" /><entity charOffset="56-59" id="DDI-PubMed.25636696.s8.e2" text="TOR" /><pair ddi="false" e1="DDI-PubMed.25636696.s8.e0" e2="DDI-PubMed.25636696.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25636696.s8.e0" e2="DDI-PubMed.25636696.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s8.e0" e2="DDI-PubMed.25636696.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s8.e1" e2="DDI-PubMed.25636696.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s8.e1" e2="DDI-PubMed.25636696.s8.e2" /></sentence><sentence text=" Tolerability assessments included the frequency of adverse events and an investigator assessment of global tolerability" /><sentence text="" /><sentence text="Mean (SD) age of the 22 patients treated was 54" /><sentence text="0 (8" /><sentence text="1) years and body mass index was 27" /><sentence text="1 (3" /><sentence text="7) kg/m(2)" /><sentence text=" Coadministration of empagliflozin with HCTZ or TOR had no effect on exposure to empagliflozin, HCTZ, or TOR"><entity charOffset="21-34" id="DDI-PubMed.25636696.s16.e0" text="empagliflozin" /><entity charOffset="40-44" id="DDI-PubMed.25636696.s16.e1" text="HCTZ" /><entity charOffset="81-94" id="DDI-PubMed.25636696.s16.e2" text="empagliflozin" /><entity charOffset="96-100" id="DDI-PubMed.25636696.s16.e3" text="HCTZ" /><entity charOffset="48-51" id="DDI-PubMed.25636696.s16.e4" text="TOR" /><entity charOffset="105-108" id="DDI-PubMed.25636696.s16.e5" text="TOR" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e0" e2="DDI-PubMed.25636696.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e0" e2="DDI-PubMed.25636696.s16.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e0" e2="DDI-PubMed.25636696.s16.e4" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e0" e2="DDI-PubMed.25636696.s16.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e0" e2="DDI-PubMed.25636696.s16.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e0" e2="DDI-PubMed.25636696.s16.e5" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e1" e2="DDI-PubMed.25636696.s16.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e1" e2="DDI-PubMed.25636696.s16.e4" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e1" e2="DDI-PubMed.25636696.s16.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e1" e2="DDI-PubMed.25636696.s16.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e1" e2="DDI-PubMed.25636696.s16.e5" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e4" e2="DDI-PubMed.25636696.s16.e4" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e4" e2="DDI-PubMed.25636696.s16.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e4" e2="DDI-PubMed.25636696.s16.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e4" e2="DDI-PubMed.25636696.s16.e5" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e2" e2="DDI-PubMed.25636696.s16.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e2" e2="DDI-PubMed.25636696.s16.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e2" e2="DDI-PubMed.25636696.s16.e5" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e3" e2="DDI-PubMed.25636696.s16.e3" /><pair ddi="false" e1="DDI-PubMed.25636696.s16.e3" e2="DDI-PubMed.25636696.s16.e5" /></sentence><sentence text=" Geometric mean ratios (90% CIs) for empagliflozin AUC over a uniform dosing interval and Cmax at steady state were 107" /><sentence text="1% (90% CI, 97" /><sentence text="1-118" /><sentence text="1) and 102" /><sentence text="8% (90% CI, 88" /><sentence text="6-119" /><sentence text="3), respectively, when coadministered with HCTZ versus administration alone, and 107"><entity charOffset="43-45" id="DDI-PubMed.25636696.s23.e0" text="HCTZ" /></sentence><sentence text="8% (90% CI, 100"><entity charOffset="8-10" id="DDI-PubMed.25636696.s24.e0" text="CI" /></sentence><sentence text="1-116" /><sentence text="1) and 107" /><sentence text="5% (90% CI, 97"><entity charOffset="8-9" id="DDI-PubMed.25636696.s27.e0" text="CI" /></sentence><sentence text="9-118" /><sentence text="0), respectively, when coadministered with TOR versus administration alone"><entity charOffset="43-44" id="DDI-PubMed.25636696.s29.e0" text="TOR" /></sentence><sentence text=" For HCTZ, the geometric mean ratios for AUC over a uniform dosing interval and Cmax at steady state were 96"><entity charOffset="5-7" id="DDI-PubMed.25636696.s30.e0" text="HCTZ" /></sentence><sentence text="3% (90% CI, 89"><entity charOffset="8-11" id="DDI-PubMed.25636696.s31.e0" text="CI" /></sentence><sentence text="1-104" /><sentence text="0) and 101" /><sentence text="8% (90% CI, 88"><entity charOffset="8-9" id="DDI-PubMed.25636696.s34.e0" text="CI" /></sentence><sentence text="6-116" /><sentence text="9), respectively, and for TOR were 101"><entity charOffset="26-27" id="DDI-PubMed.25636696.s36.e0" text="TOR" /></sentence><sentence text="4% (90% CI, 99"><entity charOffset="8-10" id="DDI-PubMed.25636696.s37.e0" text="CI" /></sentence><sentence text="1-103" /><sentence text="9) and 104" /><sentence text="4% (90% CI, 93"><entity charOffset="8-9" id="DDI-PubMed.25636696.s40.e0" text="CI" /></sentence><sentence text="8-116" /><sentence text="3), respectively, for combined treatment versus administration alone" /><sentence text=" The pharmacokinetic profiles of empagliflozin, HCTZ, and TOR were similar after administration alone and in combination"><entity charOffset="33-46" id="DDI-PubMed.25636696.s43.e0" text="empagliflozin" /><entity charOffset="48-52" id="DDI-PubMed.25636696.s43.e1" text="HCTZ" /><entity charOffset="58-61" id="DDI-PubMed.25636696.s43.e2" text="TOR" /><pair ddi="false" e1="DDI-PubMed.25636696.s43.e0" e2="DDI-PubMed.25636696.s43.e0" /><pair ddi="false" e1="DDI-PubMed.25636696.s43.e0" e2="DDI-PubMed.25636696.s43.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s43.e0" e2="DDI-PubMed.25636696.s43.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s43.e1" e2="DDI-PubMed.25636696.s43.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s43.e1" e2="DDI-PubMed.25636696.s43.e2" /></sentence><sentence text=" Global tolerability was good for all patients after each treatment, and no severe or serious adverse events were reported" /><sentence text="" /><sentence text="No pharmacokinetic drug-drug interaction was observed between empagliflozin and HCTZ or TOR"><entity charOffset="62-75" id="DDI-PubMed.25636696.s46.e0" text="empagliflozin" /><entity charOffset="80-92" id="DDI-PubMed.25636696.s46.e1" text="HCTZ" /><entity charOffset="88-100" id="DDI-PubMed.25636696.s46.e2" text="TOR" /><pair ddi="false" e1="DDI-PubMed.25636696.s46.e0" e2="DDI-PubMed.25636696.s46.e0" /><pair ddi="false" e1="DDI-PubMed.25636696.s46.e0" e2="DDI-PubMed.25636696.s46.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s46.e0" e2="DDI-PubMed.25636696.s46.e2" /><pair ddi="false" e1="DDI-PubMed.25636696.s46.e1" e2="DDI-PubMed.25636696.s46.e1" /><pair ddi="false" e1="DDI-PubMed.25636696.s46.e1" e2="DDI-PubMed.25636696.s46.e2" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT01276288" /><sentence text="" /></document>